Opinion

Video

Monitoring Schedule for JAK Inhibitors in Atopic Dermatitis

Author(s):

Christopher G. Bunick, MD, PhD,Lindsay S. Ackerman, MD, FAAD

Lindsay S. Ackerman, MD, FAAD, and Jonathan Silverberg, MD, PhD, MPH, provide clinical insights on best practices for monitoring patients with atopic dermatitis who are receiving JAK inhibitors.

Video content above is prompted by the following:

  • What is the recommended monitoring schedule for JAKi? Do you communicate it with patients when selecting treatment?
Related Videos
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
Discussing 140-Week Data on Upadacitinib for Atopic Dermatitis, with Raj Chovatiya, MD, PhD
ADORING Trial Open-Label Extension: Tapinarof Cream 1% Results in Atopic Dermatitis
Related Content
Video Education Program Reduced Severity Score of Atopic Dermatitis in Pediatric Patients
November 15th 2024

Video Education Program Reduced Severity Score of Atopic Dermatitis in Pediatric Patients

Tim Smith
Advances in Pediatric Eczema Highlight 2022
December 21st 2022

Advances in Pediatric Eczema Highlight 2022

Kevin Kunzmann
Dr. Erica Spatz at Yale School of Medicine
November 12th 2024

New Study Compares Approaches to Control High Blood Pressure

Rachel Martin
How Pegloticase Plus Methotrexate is Breaking Ground in Gout Care
July 12th 2022

How Pegloticase Plus Methotrexate is Breaking Ground in Gout Care

Armand Butera
MJH Life Sciences logo over a white background. | Credit: MJH Life Sciences
November 11th 2024

MJH Life Sciences Celebrates Acquisition of Revolutionizing Atopic Dermatitis (RAD) Annual Meeting

Patrick Campbell
Dupilumab for Atopic Dermatitis Sustained Efficacy in Clinical Signs, PROs Over 3 Years
November 11th 2024

Dupilumab for Atopic Dermatitis Sustained Efficacy in Clinical Signs, PROs Over 3 Years

Tim Smith
© 2024 MJH Life Sciences

All rights reserved.